---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-018776"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:41:40.348280+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M

## Summary
- Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.
- Net loss $16.0M vs $21.4M in 2023; cash & equivalents $19.2M, runway into Q4 2025.
- Pivotal ELPIS II HLHS trial >90% enrolled; enrollment expected to complete Q2 2025.
- BLA submission for Lomecel-B (laromestrocel) in HLHS anticipated in 2026 if trial successful.
- FDA meeting for mild Alzheimer’s disease pathway expected late Q1 2025.

## SEC filing metadata
- accession: 0001213900-25-018776
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/0001213900-25-018776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/ea0232284-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-018776
- JSON: https://secwatch.observer/filing/0001213900-25-018776.json
- Plain text: https://secwatch.observer/filing/0001213900-25-018776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.